Carmen Valcarce
Chief Tech/Sci/R&D Officer bei VTV THERAPEUTICS INC.
Profil
Carmen Valcarce is currently the Chief Scientific Officer & Executive VP at vTv Therapeutics, Inc. and vTv Therapeutics LLC.
Previously, she held positions as a Project Leader at Novo Nordisk A, Senior Vice President-Scientific Liaison at VTVX Holdings I LLC, and Principal at Excorim.
She also served as an Assistant Professor at the University of Lund from 1989 to 1998.
Dr. Valcarce obtained her doctorate degree from the Universidad Autónoma de Madrid in 1988.
Aktive Positionen von Carmen Valcarce
| Unternehmen | Position | Beginn |
|---|---|---|
| VTV THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01.01.2007 |
vTv Therapeutics LLC
 vTv Therapeutics LLC Pharmaceuticals: MajorHealth Technology vTv Therapeutics LLC is a clinical-stage biopharmaceutical company which engages in the discovery and development of small molecule drug candidates to fill unmet medical needs. It focuses on treating metabolic diseases to minimize their long-term complications through end-organ protection. The company is headquartered in High Point, NC. | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Carmen Valcarce
| Unternehmen | Position | Ende |
|---|---|---|
| University of Lund | Corporate Officer/Principal | 01.01.1998 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Excorim
 Excorim Miscellaneous Commercial ServicesCommercial Services Part of Fresenius Medical Care AG, Excorim is a Swedish company that provides medical immunology research. The private company is based in Lund, Sweden. Excorim was acquired by Fresenius Hemocare from Gambro AB on December 14, 1999. | Corporate Officer/Principal | - |
VTVX Holdings I LLC
 VTVX Holdings I LLC Miscellaneous Commercial ServicesCommercial Services VTVX Holdings I LLC discovers, develops and commercializes human therapeutics to fill unmet medical needs. Its products include a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases, including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, metabolic diseases, inflammatory diseases, female sexual dysfunction, primary open angle glaucoma and cancer. The company was founded in 1998 by Dr. Adnan M. M. Mjalli and is headquartered in High Point, NC. | Corporate Officer/Principal | - |
Ausbildung von Carmen Valcarce
| Universidad Autónoma de Madrid | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| VTV THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
VTVX Holdings I LLC
VTVX Holdings I LLC Miscellaneous Commercial ServicesCommercial Services VTVX Holdings I LLC discovers, develops and commercializes human therapeutics to fill unmet medical needs. Its products include a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases, including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, metabolic diseases, inflammatory diseases, female sexual dysfunction, primary open angle glaucoma and cancer. The company was founded in 1998 by Dr. Adnan M. M. Mjalli and is headquartered in High Point, NC. | Commercial Services |
Excorim
Excorim Miscellaneous Commercial ServicesCommercial Services Part of Fresenius Medical Care AG, Excorim is a Swedish company that provides medical immunology research. The private company is based in Lund, Sweden. Excorim was acquired by Fresenius Hemocare from Gambro AB on December 14, 1999. | Commercial Services |
vTv Therapeutics LLC
vTv Therapeutics LLC Pharmaceuticals: MajorHealth Technology vTv Therapeutics LLC is a clinical-stage biopharmaceutical company which engages in the discovery and development of small molecule drug candidates to fill unmet medical needs. It focuses on treating metabolic diseases to minimize their long-term complications through end-organ protection. The company is headquartered in High Point, NC. | Health Technology |
